The biotech-MedTech CEO tackling obesity

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Dr Camilla Easter, CEO at Oxford Medical Products.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Camilla, covering:

• Training long and hard as a Veterinary Surgeon surgeon... and then deciding to pivot into biotech
• Falling in love with the freedom and excitement of a start-up biotech while learning the importance of problem-solving and storytelling
• OMP's swelling hydrogel pill that reduces the space in your stomach and surpasses your appetite
• Developing a complementary product to GLP-1s to help tackle the 2billion+ global obesity challenge in a preventative, cheap, safe manner
• How OMPs unique, patented manufacturing process led it to in-house production and not outsourcing
• Lifting the lid on a recent selection process of choosing a global CRO partner to support upcoming clinical trials

Camilla has over ten years of biotech start-up experience as CEO and COO, working exclusively on hydrogel-based therapeutics. Initially a veterinary surgeon, she has run veterinary clinical trials and launched the veterinary arm of a biotech company. Following this, she moved into the human biotech sector, where she has been involved in all aspects of start-ups, including, R&D, manufacturing scale-up, fundraising, regulatory, quality, pre-clinical and clinical trials for medical devices.

Camilla joined the OMP team in 2019, initially to evaluate OMP technology. This led to the establishment of a team and the raising of the first round of external investment in 2020.

OMP has developed Sirona, which, taken as a pill, rapidly expands in the stomach to create a sustained feeling of appetite suppression. Sirona remains in the stomach 24/7 for several days before breaking down and passing naturally. Since 2020, they have completed preclinical testing and phase 1 clinical trials. Sirona is now in phase 2a for obesity at three NHS sites, with results expected in Q4 2024.

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.